CorMedix

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase III clinical study of a novel anti-infective solution, Neutrolin in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix's first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also had designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world.

Type
Public
HQ
Bedminster Township, US
Founded
2006
Size (employees)
9 (est)
CorMedix was founded in 2006 and is headquartered in Bedminster Township, US

CorMedix Office Locations

CorMedix has an office in Bedminster Township
Bedminster Township, US (HQ)
200 1430 Us 206

CorMedix Data and Metrics

CorMedix Financial Metrics

CorMedix's revenue was reported to be $39.6 k in Q1, 2017
USD

Revenue (Q1, 2017)

39.6 k

Gross profit (Q1, 2017)

133.1 k

Gross profit margin (Q1, 2017), %

337%

Net income (Q1, 2017)

(7.6 m)

EBIT (Q1, 2017)

(7.6 m)

Market capitalization (25-Jul-2017)

15.8 m

Cash (31-Mar-2017)

6.8 m
CorMedix's current market capitalization is $15.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 k189.3 k210.1 k224.1 k

Revenue growth, %

9359%11%7%

Cost of goods sold

201.6 k445.8 k318.7 k366.7 k

Gross profit

(199.6 k)(256.5 k)(108.6 k)(142.6 k)

Gross profit Margin, %

(9975%)(136%)(52%)(64%)

Operating expense total

4.7 m8.6 m16.5 m24.6 m

EBIT

(4.9 m)(8.9 m)(16.7 m)(24.8 m)

EBIT margin, %

(245647%)(4703%)(7926%)(11049%)

Interest expense

1.3 k

Interest income

6682.7 k60.4 k126.8 k

Pre tax profit

(9.1 m)

Net Income

(55.4 m)(20.5 m)(18.2 m)(24.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

39.7 k52.4 k31.3 k120 k35.9 k41.4 k16.5 k44.5 k39.6 k

Cost of goods sold

(54.5 k)(36.7 k)(17.3 k)(101.8 k)(35.4 k)(50.2 k)(187.2 k)(43.9 k)(93.6 k)

Gross profit

94.2 k89.1 k48.6 k221.8 k71.3 k91.7 k203.7 k88.4 k133.1 k

Gross profit Margin, %

237%170%155%185%198%221%1234%199%337%

R&D expense

(171.9 k)(292.7 k)(1.2 m)(1.8 m)(1.8 m)(2.1 m)(2.8 m)(6.8 m)(4.9 m)

General and administrative expense

(1.7 m)(1.6 m)(4.3 m)(2.4 m)(2.9 m)(2.2 m)(2 m)(2.3 m)(2.6 m)

Operating expense total

(1.9 m)(1.9 m)(5.5 m)(4.2 m)(4.7 m)(4.3 m)(4.7 m)(9.2 m)(7.6 m)

EBIT

(1.9 m)(1.9 m)(5.5 m)(4.1 m)(4.7 m)(4.3 m)(4.9 m)(9.2 m)(7.6 m)

EBIT margin, %

(4757%)(3554%)(17582%)(3446%)(13110%)(10286%)(29751%)(20602%)(19260%)

Interest expense

(859)(3.7 k)(1.6 k)(992)(41)

Interest income

9876455438.8 k25 k31.6 k29.4 k32.9 k23.4 k

Net Income

3.5 m(5 m)(5.5 m)(4.1 m)(4.7 m)(4.2 m)(4.9 m)(9.1 m)(7.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.4 m4.3 m11.8 m8.1 m

Inventories

80 k166.7 k

Current Assets

2.9 m5 m37.1 m21.8 m

PP&E

36.1 k41.5 k37.9 k69.7 k

Total Assets

3 m5.1 m37.1 m21.9 m

Accounts Payable

939.8 k893.4 k1.7 m1.6 m

Current Liabilities

1.7 m1.4 m3.1 m4.1 m

Total Liabilities

4.1 m

Additional Paid-in Capital

51.7 m79.7 m128.3 m136.9 m

Retained Earnings

(76.2 m)(94.4 m)(119.2 m)

Total Equity

(4 m)3.6 m34 m17.8 m

Financial Leverage

-0.7 x1.4 x1.1 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

7.7 m5.9 m8.8 m24.1 m14.2 m13.2 m12 m9.8 m6.8 m

Inventories

278 k677.4 k461.4 k715 k699.1 k333.9 k157.5 k118.2 k94.9 k

Current Assets

8.2 m6.8 m9.7 m38.7 m39.3 m33.6 m31.2 m28.8 m14.9 m

PP&E

54.2 k46.9 k47 k44.7 k41.1 k34.8 k31.9 k75.8 k63.2 k

Total Assets

8.3 m6.8 m9.8 m38.8 m39.3 m33.6 m31.2 m28.8 m14.9 m

Accounts Payable

848.6 k740.3 k1.4 m1.1 m1.4 m1.6 m1.1 m1.8 m1.7 m

Current Liabilities

1.2 m1.2 m2.1 m1.9 m2.9 m3.1 m3.1 m5 m3.9 m

Additional Paid-in Capital

67.3 m79.4 m89.2 m122.6 m126.8 m129 m131.5 m136.3 m137.7 m

Retained Earnings

(74 m)(81.7 m)(85.8 m)(90.5 m)(98.6 m)(103.5 m)(112.6 m)(126.8 m)

Total Equity

(1.6 m)5.6 m7.6 m36.9 m36.4 m30.5 m28.1 m23.8 m11 m

Financial Leverage

-5.2 x1.2 x1.3 x1.1 x1.1 x1.1 x1.1 x1.2 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(9.1 m)(20.5 m)(18.2 m)(24.6 m)

Inventories

80 k

Accounts Payable

939.8 k893.4 k1.7 m1.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

3.5 m(5 m)(5.5 m)(4.1 m)(4.7 m)(4.2 m)(4.9 m)(9.1 m)(7.6 m)

Inventories

278 k677.4 k

Accounts Payable

848.6 k740.3 k1.4 m1.1 m1.4 m1.6 m1.1 m1.8 m1.7 m
USDY, 2017

Revenue/Employee

4.4 k

Financial Leverage

1.4 x

CorMedix Market Value History

CorMedix Online and Social Media Presence

CorMedix Company Life and Culture

You may also be interested in